Evidence map›Paper›PMID 38381158›Full record

ArticleJournal of molecular medicine (Berlin, Germany)2024

Novel high-yield potato protease inhibitor panels block a wide array of proteases involved in viral infection and crucial tissue damage.

Nienke Visser, Laure C M Herreman, Jennifer Vandooren, Rafaela Vaz Sousa Pereira, Ghislain Opdenakker, Robin E J Spelbrink, Maarten H Wilbrink, Edwin Bremer, Reinoud Gosens, Martijn C Nawijn and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of molecular medicine (Berlin, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.9field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Nienke VisserDepartment of Hematology, Cancer Research Center Groningen, University Medical Center Groningen, University of Groningen, 9713 GZ, Groningen, The Netherlands.
Laure C M HerremanAvebe Innovation Center Groningen, 9747 AW, Groningen, The Netherlands.
Jennifer VandoorenLaboratory of Immunobiology, Rega Institute for Medical Research, Department of Microbiology, Immunology and Transplantation, KU Leuven, 3000, Louvain, Belgium.
Rafaela Vaz Sousa PereiraLaboratory of Immunobiology, Rega Institute for Medical Research, Department of Microbiology, Immunology and Transplantation, KU Leuven, 3000, Louvain, Belgium.
Ghislain OpdenakkerLaboratory of Immunobiology, Rega Institute for Medical Research, Department of Microbiology, Immunology and Transplantation, KU Leuven, 3000, Louvain, Belgium.
Robin E J SpelbrinkAvebe Innovation Center Groningen, 9747 AW, Groningen, The Netherlands.
Maarten H WilbrinkAvebe Innovation Center Groningen, 9747 AW, Groningen, The Netherlands.
Edwin BremerDepartment of Hematology, Cancer Research Center Groningen, University Medical Center Groningen, University of Groningen, 9713 GZ, Groningen, The Netherlands.
Reinoud GosensDepartment of Molecular Pharmacology, University Medical Center Groningen, 9713 GZ, Groningen, The Netherlands.
Martijn C NawijnGroningen Research Institute for Asthma and COPD (GRIAC) Research Institute, University of Groningen, 9713 GZ, Groningen, The Netherlands.
Heidi H van der Ende-MetselaarDepartment of Medical Microbiology and Infection Prevention, University Medical Center Groningen, University of Groningen, 9713 GZ, Groningen, The Netherlands.
Jolanda M SmitDepartment of Medical Microbiology and Infection Prevention, University Medical Center Groningen, University of Groningen, 9713 GZ, Groningen, The Netherlands.
Marc C LausAvebe Innovation Center Groningen, 9747 AW, Groningen, The Netherlands.
Jon D LamanDepartment of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, 9713 GZ, Groningen, The Netherlands. j.d.laman@umcg.nl.ORCID 0000-0001-5085-9807
University Medical Center Groningen · NLArt Innovation (Netherlands) · NLRega Institute for Medical Research · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Viruses critically rely on various proteases to ensure host cell entry and replication. In response to viral infection, the host will induce acute tissue inflammation pulled by granulocytes. Upon hyperactivation, neutrophil granulocytes may cause undue tissue damage through proteolytic degradation of the extracellular matrix. Here, we assess the potential of protease inhibitors (PI) derived from potatoes in inhibiting viral infection and reducing tissue damage. The original full spectrum of potato PI was developed into five fractions by means of chromatography and hydrolysis. Individual fractions showed varying inhibitory efficacy towards a panel of proteases including trypsin, chymotrypsin, ACE2, elastase, and cathepsins B and L. The fractions did not interfere with SARS-CoV-2 infection of Vero E6 cells in vitro. Importantly, two of the fractions fully inhibited elastin-degrading activity of complete primary human neutrophil degranulate. These data warrant further development of potato PI fractions for biomedical purposes, including tissue damage crucial to SARS-CoV-2 pathogenesis. KEY MESSAGES: Protease inhibitor fractions from potato differentially inhibit a series of human proteases involved in viral replication and in tissue damage by overshoot inflammation. Protease inhibition of cell surface receptors such as ACE2 does not prevent virus infection of Vero cells in vitro. Protease inhibitors derived from potato can fully inhibit elastin-degrading primary human neutrophil proteases. Protease inhibitor fractions can be produced at high scale (hundreds of thousands of kilograms, i.e., tons) allowing economically feasible application in lower and higher income countries.

Indexed as

COVID-19Solanum tuberosumAngiotensin-Converting Enzyme 2AnimalsAntiviral AgentsChlorocebus aethiopsElastinEnzyme InhibitorsHumansInflammationPeptide HydrolasesProtease InhibitorsVero CellsAngiotensin-Converting Enzyme 2Antiviral AgentsElastinEnzyme InhibitorsPeptide HydrolasesProtease InhibitorsCovid-19PotatoProtease inhibitorTissue preteolysisViral infection

Identifiers

PMID38381158
PMCPMC10963447
OpenAlexW4392004195

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.